Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis

Atezolizumab plus bevacizumab in patients with unresectable or metastatic mucosal melanoma: 3‐year survival update and multi‐omics analysis

Abstract Background Atezolizumab plus bevacizumab has shown promising efficacy in advanced mucosal melanoma in the multi‐centre phase II study. This report updates 3‐year survival outcomes and multi‐omics analysis to identify potential response biomarkers. Methods Forty‐three intention‐to‐treat (ITT...

Full description

Saved in:
Bibliographic Details
Main Authors: Jie Dai, Tianxiao Xu, Lifeng Li, Meiyu Fang, Jing Lin, Jun Cao, Xue Bai, Caili Li, Xiaoting Wei, Junjie Gu, Yaoyao Liu, Xuan Gao, Xuefeng Xia, Jun Guo, Yu Chen, Lili Mao, Lu Si
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Clinical and Translational Medicine
Subjects:
atezolizumab
bevacizumab
immunotherapy
mucosal melanoma
VEGF inhibitor
Online Access:https://doi.org/10.1002/ctm2.70169
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/ctm2.70169

Similar Items